Hualan Bio, officially known as Hualan Biological Engineering Inc., is a leading biotechnology company headquartered in China (CN). Established in 1992, Hualan Bio has made significant strides in the biopharmaceutical industry, focusing on the research, development, and production of vaccines and diagnostic reagents. With major operational regions across Asia and expanding globally, the company has positioned itself as a key player in public health. Hualan Bio's core products include a range of human and animal vaccines, as well as innovative diagnostic solutions that stand out for their quality and efficacy. The company has achieved notable milestones, including several national and international certifications, reinforcing its commitment to safety and excellence. As a pioneer in the biotechnology sector, Hualan Bio continues to contribute to advancements in healthcare, solidifying its reputation as a trusted name in the industry.
How does Hualan Bio's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hualan Bio's score of 22 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hualan Bio, headquartered in China (CN), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As there is no emissions data available, it is important to note that Hualan Bio's climate commitments and initiatives are not detailed in the provided information. The company does not inherit emissions data from a parent organization, and thus operates independently in its climate strategy. In the context of the industry, Hualan Bio may be expected to align with global trends towards sustainability and carbon neutrality, but specific actions or targets have not been disclosed.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hualan Bio has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
